Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

United Therapeutics (UTHR) Operating Income (2016 - 2026)

United Therapeutics' Operating Income history spans 17 years, with the latest figure at $356.7 million for Q4 2025.

  • On a quarterly basis, Operating Income changed 0.28% to $356.7 million in Q4 2025 year-over-year; TTM through Dec 2025 was $1.5 billion, a 8.39% increase, with the full-year FY2025 number at $1.5 billion, up 8.39% from a year prior.
  • Operating Income hit $356.7 million in Q4 2025 for United Therapeutics, down from $388.5 million in the prior quarter.
  • Over the last five years, Operating Income for UTHR hit a ceiling of $388.5 million in Q3 2025 and a floor of -$64.8 million in Q1 2021.
  • Historically, Operating Income has averaged $279.5 million across 5 years, with a median of $313.8 million in 2022.
  • Biggest five-year swings in Operating Income: plummeted 138.87% in 2021 and later soared 544.44% in 2022.
  • Tracing UTHR's Operating Income over 5 years: stood at $169.8 million in 2021, then rose by 3.42% to $175.6 million in 2022, then skyrocketed by 48.12% to $260.1 million in 2023, then surged by 37.52% to $357.7 million in 2024, then dropped by 0.28% to $356.7 million in 2025.
  • Business Quant data shows Operating Income for UTHR at $356.7 million in Q4 2025, $388.5 million in Q3 2025, and $364.5 million in Q2 2025.